Impact of federal vaccine policy changes and ongoing debate on cancer patients and survivors’ attitudes toward vaccines.
TL;DR
Cancer patients and survivors demonstrate strong support for vaccination but report confusion from evolving federal guidance that may affect uptake, alongside opportunities to build trust in emerging technologies such as mRNA.
Abstract
452 Background: Immunizations are an essential part of cancer care. Yet, vaccination rates have declined steadily since 2020 as states increasingly loosen vaccine requirements, creating regional pockets of vulnerability and increasing the risk of outbreaks threatening the health of cancer patients. The use of mRNA technology in vaccines, is becoming an increasingly prominent and often polarizing topic in public discussions and policy efforts. These trends are occurring alongside proposed changes to federal vaccine policy, creating uncertainty for cancer patients, families, and healthcare providers. Methods: We analyzed data from the 2026 American Cancer Society Cancer Action Network (ACS CAN) Survivor Views survey, a national research panel of cancer patients and survivors, to assess attitudes and decision-making related to vaccination and mRNA vaccine technology. Results: A total of 1,445 patients with cancer and survivors responded to the survey, 86% female, 39% within 3 years of diagnosis, and 27% currently in treatment. Respondents consistently endorsed the importance of vaccination to protect themselves and their communities: 86% supported school-entry vaccination requirements, with particularly high support among patients age 65 (91%) and older and those who are currently undergoing treatment (89%). Most respondents (83%) report that it is important that people around them, including in schools (85%) and health care settings (88%), are up to date on recommended vaccinations, and more than three-quarters (76%) oppose state policies that limit access to vaccines. Despite the strong importance of community immunization to this vulnerable population, the survey also found confusion related to changing federal recommendations impacting vaccine decision-making, with nearly one in six respondents (16%) reporting that they delayed or skipped a recommended vaccine due to uncertainty. The survey also found strong support for oncology applications of mRNA vaccines. While over half of respondents (55%) initially say they don’t know enough about mRNA vaccines to have formed an opinion, those who are aware have are more positive view by a ratio of three to one (35% positive, 11% negative). After learning more about the potential for mRNA vaccines in cancer treatment, 84% agree that the United Sates should invest in medical research related to mRNA technology. Conclusions: Cancer patients and survivors demonstrate strong support for vaccination but report confusion from evolving federal guidance that may affect uptake. Support for evidence-based vaccine policies, along with clear, consistent communication and patient-centered engagement is essential, alongside opportunities to build trust in emerging technologies such as mRNA.